Close
18/03/2014
The public-private partnership ESTEVE-UAB is bearing fruit
ESTEVE has announced the signing of two agreements that will enable it to progress the development of its gene therapeutic for the treatment of Sanfilippo A Syndrome and begin a phase I/II clinical trial in 2015. The agreements are with the North American biotechnology company REGENX Biosciences, LLC (REGENX) and with the French non for profit organization GÉNÉTHON.
 
Sanfilippo A is a rare and devastating neurodegenerative disease that affects approximately 1 in every 100.000 children that rarely survive past adolescence.

This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fàtima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autònoma de Barcelona (UAB).

In this partnership, ESTEVE leads all activities associated with the management and protection of intellectual property, regulatory activities, the coordination and supervision of GMP manufacturing, the preclinical toxicology studies as well as all clinical development.
The CBATEG research team at the UAB brings to the partnership their scientific know-how and expertise in gene therapy including viral vector design and the development of preclinical disease models.

Press release

More news

07/05/2014 The new Hewlett-Packard world development center for 3D printers will be in Barcelona 28/04/2014 Loss of memory reversed in Alzheimer's mice models 25/04/2014 More than 30 companies attended the ALBA industry workshop 15/04/2014 European Commission names Barcelona first European Capital of Innovation 11/04/2014 Visit of the Spanish State Secretary for research to the Barcelona Synchrotron Park (BSP) 02/04/2014 High-precision molding in the PTV
41 42 43 44 45 46 47 48 49